Form 4: Edgewise Therapeutics CEO Kevin Koch Reports Stock Transactions

CEO Kevin Koch reports the vesting of Restricted Stock Units and subsequent sale of shares to cover tax obligations.

Summary

• On May 1, 2025, Kevin Koch, the President and CEO of Edgewise Therapeutics, Inc., acquired 10,417 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Also on May 1, 2025, Koch disposed of 10,417 shares to cover statutory tax withholding obligations related to the RSU vesting.
• On May 2, 2025, Koch sold 4,276 shares of common stock at an average price of $16.4542.
• Following these transactions, Koch directly owns 20,619 shares of common stock.
• Koch also indirectly owns 259,554 shares through KTK Family Enterprise, LLC, and 26,410 shares each through Adrienne R. Koch Heritage Trust, Matthew K. Koch Heritage Trust, and Nicole M. Soldow Heritage Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't convey any particularly positive or negative sentiment about the company's performance or future prospects.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry. These transactions are often related to executive compensation and do not necessarily indicate a change in the company's prospects.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold.

Key Dates

Keywords

Edgewise Therapeutics, Kevin Koch, Stock Transactions, Form 4, RSU, Beneficial Ownership, Securities